Showing results (181-190 of 279) with videos related to
Sort By:
Pageof 28
Prostate Cancer and Prostatic Diseases|September 14, 2021
Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trialsBertrand F Tombal, Stephen J Freedland, Andrew J Armstrong, et al.Medicine|July 7, 2017
Post hoc analyses of East Asian patients from the randomized placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naïve, metastatic castration-resistant prostate cancerChoung Soo Kim, Young Deuk Choi, Sang Eun Lee, et al.Clinical Genitourinary Cancer|January 6, 2015
Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSFRahul R Aggarwal, Tomasz M Beer, Vivian K Weinberg, et al.The Lancet. Oncology|October 17, 2017
Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trialTomasz M Beer, Sebastien J Hotte, Fred Saad, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2009
Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortiumJonathan E Rosenberg, Charles J Ryan, Vivian K Weinberg, et al.Clinical Genitourinary Cancer|October 1, 2008
Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanesTomasz M Beer, Bryan Goldman, Timothy W Synold, et al.European Urology|September 6, 2024
Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION TrialAndrew J Armstrong, Oliver Sartor, Johann de Bono, et al.Journal of Vascular and Interventional Radiology : JVIR|May 28, 2017
CT-Guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer: Factors Predictive of Maximum Tumor YieldMichael G Holmes, Erik Foss, Gabby Joseph, et al.Oncotarget|October 27, 2017
Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancerJennifer Podolak, Kristi Eilers, Timothy Newby, et al.Proceedings of the National Academy of Sciences of the United States of America|July 11, 2006
A molecular correlate to the Gleason grading system for prostate adenocarcinomaLawrence True, Ilsa Coleman, Sarah Hawley, et al.Pageof 28